Ji Yeon Yang
University of Texas MD Anderson Cancer Center
12 Papers
30 Citations
Ji Yeon Yang is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Ovarian cancer & Ovarian carcinoma. The author has an hindex of 10, co-authored 12 publications.
Chat about Author
Papers
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein,Rehan Akbani,Bradley M. Broom,Wenyi Wang,Roeland Verhaak,David J. McConkey,Seth P. Lerner,Margaret Morgan,Chad J. Creighton,Carolyn L. Smith,Andrew D. Cherniack,Jaegil Kim,Chandra Sekhar Pedamallu,Michael S. Noble,Hikmat Al-Ahmadie,Victor E. Reuter,Jonathan E. Rosenberg,Dean F. Bajorin,Bernard H. Bochner,David B. Solit,Theresa M. Koppie,Brian D. Robinson,Dmitry A. Gordenin,David C. Fargo,Leszek J. Klimczak,Steven A. Roberts,Jessie Au,Peter W. Laird,Toshinori Hinoue,Nikolaus Schultz,Ricardo Ramirez,Donna E. Hansel,Katherine A. Hoadley,William Y. Kim,Jeffrey S. Damrauer,Stephen B. Baylin,Andrew J. Mungall,A. Gordon Robertson,Andy Chu,David J. Kwiatkowski,Carrie Sougnez,Kristian Cibulskis,Lee Lichtenstein,Andrey Sivachenko,Chip Stewart,Michael S. Lawrence,Gad Getz,Eric S. Lander,Stacey B. Gabrie,Lawrence A. Donehower,Scott L. Carter,Gordon Saksena,Steven E. Schumacher,Samuel S. Freeman,Joonil Jung,Ami S. Bhatt,Trevor J. Pugh,Rameen Beroukhim,Matthew Meyerson,Adrian Ally,Miruna Balasundaram,Yaron S.N. Butterfield,Noreen Dhalla,Carrie Hirst,Robert A. Holt,Steven J.M. Jones,Darlene Lee,Haiyan I. Li,Marco A. Marra,Michael Mayo,Richard A. Moore,Jacqueline E. Schein,Payal Sipahimalani,Angela Tam,Nina Thiessen,Tina Wong,Natasja Wye,Reanne Bowlby,Eric Chuah,Ranabir Guin,Hui Shen,Moiz S. Bootwalla,Timothy J. Triche,Phillip H. Lai,David Van Den Berg,Daniel J. Weisenberger,Saianand Balu,Tom Bodenheimer,Alan P. Hoyle,Stuart R. Jefferys,Shaowu Meng,Lisle E. Mose,Janae V. Simons,Mathew G. Soloway,Junyuan Wu,Joel S. Parker,D. Neil Hayes,Jeffrey Roach,Elizabeth Buda,Corbin D. Jones,Piotr A. Mieczkowski,Donghui Tan,Umadevi Veluvolu,Scot Waring,J. Todd Auman,Charles M. Perou,Matthew D. Wilkerson,Netty Santoso,Michael Parfenov,Xiaojia Ren,Angeliki Pantazi,Angela Hadjipanayis,Jonathan G. Seidman,Raju Kucherlapati,Semin Lee,Lixing Yang,Peter J. Park,Andrew Wei Xu,Alexei Protopopov,Jianhua Zhang,Christopher A. Bristow,Harshad S. Mahadeshwar,Sahil Seth,Xingzhi Song,Jiabin Tang,Dong Zeng,Lynda Chin,Lynda Chin,Charles C. Guo,Tod D. Casasent,Wenbin Liu,Zhenlin Ju,Thomas C. Motter,Bo Peng,Michael Ryan,Xiaoping Su,Ji Yeon Yang,Philip L. Lorenzi,Hui Yao,Nianxiang Zhang,Jiexin Zhang,Gordon B. Mills,Juok Cho,Daniel DiCara,Scott Frazer,Nils Gehlenborg,David I. Heiman,Pei Lin,Yingchun Liu,Petar Stojanov,Doug Voet,Hailei Zhang,Lihua Zou,Brady Bernard,Dick Kreisberg,Sheila Reynolds,Hector Rovira,Ilya Shmulevich,Jianjiong Gao,Anders Jacobsen,B. Arman Aksoy,Yevgeniy Antipin,Giovanni Ciriello,Gideon Dresdner,Benjamin Gross,William Lee,Boris Reva,Ronglai Shen,Rileen Sinha,S. Onur Sumer,Nils Weinhold,Marc Ladanyi,Chris Sander,Christopher C. Benz,Daniel E. Carlin,David Haussler,Sam Ng,Evano Paull,Joshua M. Stuart,Jing Zhu,Yuexin Liu,Wei Zhang,Barry S. Taylor,Tara M. Lichtenberg,Erik Zmuda,Thomas Barr,Aaron D. Black,Myra M. George,Benjamin Hanf,Carmen Helsel,Cynthia McAllister,Nilsa C. Ramirez,Nilsa C. Ramirez,Teresa R. Tabler,Stephanie Weaver,Lisa Wise,Jay Bowen,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Weiguo Jian,Sebrina A Tello,Michael Ittman,Patricia Castro,Whitney D. McClenden,Richard A. Gibbs,Charles Saller,Katherine Tarvin,Jennifer DiPiero,Jennifer Owens,Roni J. Bollag,Qiang Li,Paul M. Weinberger,Christine Czerwinski,Lori Huelsenbeck-Dill,Mary Iacocca,Nicholas J. Petrelli,Brenda Rabeno,Pat Swanson,Troy Shelton,Erin Curley,Johanna Gardner,David Mallery,Robert Penny,Nguyen Van Bang,Phan Thi Hanh,Bernard Kohl,Xuan Van Le,Bui Duc Phu,Richard Thorp,Nguyen Viet Tien,Le Quang Vinh,George E. Sandusky,Eric J. Burks,Kimberly R. Christ,Jason R. Gee,Antonia H. Holway,Alireza Moinzadeh,Andrea Sorcini,Travis Sullivan,Ilana Rebecca Garcia-Grossman,Ashley Marie Regazzi,Lori Boice,W.K. Rathmell,Leigh B. Thorne,Sheldon I. Bastacky,Benjamin Davies,Rajiv Dhir,Jeffrey R. Gingrich,Ronald L. Hrebinko,Jodi K. Maranchie,Joel B. Nelson,Anil V. Parwani,Wiam Bshara,Carmelo Gaudioso,Carl Morrison,Vina Alexopoulou,John M. S. Bartlett,Jay Engel,Sugy Kodeeswaran,Tatjana Antic,Peter H. O'Donnell,Norm D. Smith,Gary D. Steinberg,Sophie C. Egea,Carmen Gomez-Fernandez,Lynn M. Herbert,Merce Jorda,Mark S. Soloway,Allison Beaver,Suzie Carter,Payal Kapur,Cheryl M. Lewis,Yair Lotan,Jolanta Bondaruk,Bogdan Czerniak,Eila C. Skinner,Kenneth Aldape,Mark A. Jensen,Ari B. Kahn,Todd Pihl,David Pot,Deepak Srinivasan,Yunhu Wan,Martin L. Ferguson,Jean C. Zenklusen,Tanja Davidsen,John A. Demchok,Kenna R. Mills Shaw,Kenna R. Mills Shaw,Margi Sheth,Roy Tarnuzzer,Zhining Wang,Liming Yang,Carolyn M. Hutter,Bradley A. Ozenberger,Heidi J. Sofia,Greg Eley +296 more
TL;DR: Ch Chromatin regulatory genes were more frequently mutated in urothelial carcinoma than in any other common cancer studied so far, indicating the future possibility of targeted therapy for chromatin abnormalities.
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Roel G.W. Verhaak,Pablo Tamayo,Ji Yeon Yang,Diana D. Hubbard,Hailei Zhang,Chad J. Creighton,Sian Fereday,Michael S. Lawrence,Scott L. Carter,Craig H. Mermel,Aleksandar Kostic,Dariush Etemadmoghadam,Gordon Saksena,Kristian Cibulskis,Sekhar Duraisamy,Keren Levanon,Keren Levanon,Carrie Sougnez,Aviad Tsherniak,Sebastian Gomez,Robert C. Onofrio,Stacey Gabriel,Lynda Chin,Nianxiang Zhang,Paul T. Spellman,Yiqun Zhang,Rehan Akbani,Katherine A. Hoadley,Ari B. Kahn,Martin Köbel,David G. Huntsman,Robert A. Soslow,Anna deFazio,Michael J. Birrer,Joe W. Gray,John N. Weinstein,David D.L. Bowtell,Ronny Drapkin,Jill P. Mesirov,Gad Getz,Douglas A. Levine,Matthew Meyerson +41 more
TL;DR: The spectrum of outcomes observed here and their association with CLOVAR signatures suggests variations in underlying tumor biology, which may provide a rationale for optimal combination of patient and treatment regimens.
A pan-cancer proteomic perspective on The Cancer Genome Atlas
Rehan Akbani,Patrick Kwok Shing Ng,Henrica M.J. Werner,Maria Shahmoradgoli,Fan Zhang,Zhenlin Ju,Wenbin Liu,Ji Yeon Yang,Kosuke Yoshihara,Jun Li,Shiyun Ling,Elena G. Seviour,Prahlad T. Ram,John D. Minna,Lixia Diao,Pan Tong,John V. Heymach,Steven M. Hill,Frank Dondelinger,Nicolas Städler,Nicolas Städler,Lauren Averett Byers,Funda Meric-Bernstam,John N. Weinstein,Bradley M. Broom,Roeland Verhaak,Han Liang,Sach Mukherjee,Sach Mukherjee,Yiling Lu,Gordon B. Mills +30 more
TL;DR: R reverse-phase protein arrays are used to analyze 3,467 patient samples from 11 TCGA “Pan-Cancer” diseases, using 181 high-quality antibodies that target 128 total proteins and 53 post-translationally modified proteins to provide a framework for determining the prognostic, predictive and therapeutic relevance of the functional proteome.
TCPA: a resource for cancer functional proteomics data
Jun Li,Yiling Lu,Rehan Akbani,Zhenlin Ju,Paul Roebuck,Wenbin Liu,Ji Yeon Yang,Bradley M. Broom,Roeland Verhaak,David W. Kane,David W. Kane,Chris Wakefield,John N. Weinstein,Gordon B. Mills,Han Liang +14 more
TL;DR: This work has generated the largest publicly available collection of cancer functional proteomics data with parallel DNA and RNA data over a large number of tumor and cell line samples using reverse-phase protein arrays (RPPAs).
Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo
Fiona Simpkins,Pedro Hevia-Paez,Jun Sun,Wendy Ullmer,Candace A. Gilbert,Thiago G. da Silva,Ali Pedram,Ellis R. Levin,Isildinha M. Reis,Brian Rabinovich,Diana J. Azzam,Xiang Xi Xu,Tan A. Ince,Ji Yeon Yang,Roel G.W. Verhaak,Yiling Lu,Gordon B. Mills,Joyce M. Slingerland +17 more
TL;DR: Saracatinib augments effects of fulvestrant by opposing estrogen-mediated Src activation and target gene expression, increasing cell-cycle arrest, and impairing survival, all of which would oppose antiestrogen resistance in these ER+ ovarian cancer models.
63